<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00781664</url>
  </required_header>
  <id_info>
    <org_study_id>AN2718-TP-101</org_study_id>
    <nct_id>NCT00781664</nct_id>
  </id_info>
  <brief_title>Cumulative Irritation Test</brief_title>
  <official_title>21-Day Cumulative Irritation Test</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the cumulative irritation potential of the products
      listed by the Sponsor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy, adult volunteers of either sex will be patched daily on his/her back with multiple
      strengths of AN2718 in 2 different topical dosage forms and an active comparator over the
      course of 21 consecutive days. Twenty-four hours after each application, the patches will be
      removed and the site evaluated using a five-point scale for irritation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Irritation Score (5-point scale)</measure>
    <time_frame>Daily for 21 days</time_frame>
  </primary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Tinea Pedis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AN2718 Cream SF Vehicle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AN2718 Cream SF, 0.3%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AN2718 Cream SF, 1%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AN2718 Gel Vehicle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AN2718 Gel, 1.5%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AN2718 Gel, 2.5%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AN2718 Gel, 5%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>H</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AN2718 Gel, 7.5%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sodium Lauryl Sulfate, 0.5%</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>AN2718</intervention_name>
    <description>AN2718 Cream SF Vehicle, Daily for up to 21 days</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AN2718</intervention_name>
    <description>AN2718 Cream SF, 0.3%, Daily for up to 21 days</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AN2718</intervention_name>
    <description>AN2718 Cream SF, 1%, Daily for up to 21 days</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>AN2718</intervention_name>
    <description>AN2718 Gel Vehicle, Daily for up to 21 days</description>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AN2718</intervention_name>
    <description>AN2718 Gel, 1.5%, Daily for up to 21 days</description>
    <arm_group_label>E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AN2718</intervention_name>
    <description>AN2718 Gel, 2.5%, Daily for up to 21 days</description>
    <arm_group_label>F</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AN2718</intervention_name>
    <description>AN2718 Gel, 5%, Daily for up to 21 days</description>
    <arm_group_label>G</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AN2718</intervention_name>
    <description>AN2718 Gel, 7.5%, Daily for up to 21 days</description>
    <arm_group_label>H</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sodium Lauryl Sulfate</intervention_name>
    <description>Sodium Lauryl Sulfate, 0.5%, Daily for up to 21 days</description>
    <arm_group_label>I</arm_group_label>
    <other_name>SLS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects must meet all of the following criteria for inclusion in the study.

          1. Healthy volunteers of either sex, at least 18 years of age or older.

          2. Females must be of non-childbearing potential (i.e., post-menopausal or surgically
             sterile [bilateral oophorectomy and/or total hysterectomy]). All females must submit
             to a urine pregnancy test and have a negative result at Day 1 and at the final study
             visit.

          3. Subjects may be of any skin type or race providing their degree of skin pigmentation
             does not interfere with making readings of skin reactions.

          4. Willingness to follow the study procedures and complete the study.

          5. Written informed consent obtained.

        Exclusion Criteria:

          1. Any skin disease that would in any way confound interpretation of the study results.
             Atopic dermatitis/eczema, psoriasis will be excluded.

          2. Chronic asthma will be excluded.

          3. Pregnant or nursing mothers.

          4. A history of sensitivity to any component of any of the formulations.

          5. Use of chronic medications (such as antihistamines, corticosteroids, analgesics and
             anti-inflammatories) for one week before and during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lee Zane, M.D., M.A.S.</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Education and Research Foundation, Inc.</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2008</study_first_submitted>
  <study_first_submitted_qc>October 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2008</study_first_posted>
  <last_update_submitted>November 19, 2008</last_update_submitted>
  <last_update_submitted_qc>November 19, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2008</last_update_posted>
  <responsible_party>
    <name_title>Lee Zane, M.D., M.A.S.</name_title>
    <organization>Anacor Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinea Pedis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

